Theratechnologies (TSE:TH) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Theratechnologies has announced an FDA review date for its new tesamorelin formulation, F8, set for March 2025. If approved, this formulation will replace the current F4 version and enjoys patent protection in the U.S. until 2033. The development could impact the company’s stock performance, attracting investor attention.
For further insights into TSE:TH stock, check out TipRanks’ Stock Analysis page.
